Understanding vaccine responses in immunocompromised patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to analyze the immune responses to vaccinations against respiratory viruses in immunocompromised patients. It focuses on both early and late booster vaccinations, particularly examining virus-specific T cell responses. The study addresses the challenges faced by patients with conditions such as hematological malignancies and those undergoing immunosuppressive therapies, who are at higher risk for severe infections. By gathering immunologic data, the study seeks to improve vaccination strategies for this vulnerable population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed informed consent form
* Patients with immunosuppression either by treatment or underlying diseases
* Patients who are vaccinated or willing to be vaccinated against respiratory virus infections in ac-cordance with current recommendations
* Age of 18 years or older

Exclusion Criteria:

* Patients unwilling/ineligible for vaccination under current recommendations

Where it's running

• University Hospital Cologne
  Cologne, North Rhine-Westphalia, Germany Recruiting

Study contacts

• Study coordinator: Sibylle Mellinghoff, MD
• Email: sibylle.mellinghoff@uk-koeln.de
• Phone: +4947885523

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Optimizing antiviral treatment for immunocompromised people with COVID-19

  This trial will test whether adding remdesivir to Paxlovid or extending Paxlovid from 5 to 10 days helps immunocompromised people with asymptomatic or mild-to-moderate COVID-19.

  Recruiting at 4 sites Phase 2 University Hospital, Geneva · Basel, Basel and 3 other locations · NCT07406217

• Using CD45RA Depleted Stem Cells to Prevent Infections After Transplant

  This study is testing whether using special stem cells can help patients with high-risk leukemia recover their immune system faster and prevent infections after a stem cell transplant.

  Recruiting Phase 1/2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT06839456

• Investigating the effects of clozapine on immune function in Parkinson's disease

  This study tests how clozapine affects the immune system in people with Parkinson's disease who have psychotic symptoms, to see if it increases their risk of infections.

  Recruiting Phase 4 Centre Hospitalier Universitaire, Amiens · Salouël · NCT06634641

• Analyzing immune system issues in patients

  This study is trying to collect blood and stool samples from people with immune system problems and healthy individuals to better understand these issues and help improve treatments.

  Recruiting Karolinska Institutet · Stockholm · NCT06248957

• Optimizing antiviral therapy for immunocompromised patients with COVID-19

  This study is testing if a combination of two antiviral medications can help immunocompromised patients with mild COVID-19 feel better and if taking one of the medications for longer makes a difference.

  Recruiting at 18 sites Phase 2 ANRS, Emerging Infectious Diseases · Bordeaux, Bordeaux and 17 other locations · NCT05587894

• Strategy using bacterial DNA detection to guide antibiotics in immunocompromised patients with ventilator-associated or hospital-acquired pneumonia

  This study tests whether using a PCR-based method to tailor antibiotics in immunocompromised ICU patients with suspected VAP or HAP on mechanical ventilation can improve the use of targeted antibiotics within 24 hours of diagnosis.

  Recruiting University Hospital, Lille · Lille · NCT05405491

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.